Global Health Limited operates a network of advanced multi-specialty hospitals providing tertiary and quaternary care across India. The business is divided into mature facilities generating stable 24 to 25 percent EBITDA margins, developing hospitals scaling rapidly toward 31 to 32 percent margins, and the newly launched Noida facility currently in its ramp-up phase. Over the next 18 to 24 months, the trajectory hinges on the Noida hospital reaching 40 to 45 percent occupancy to achieve EBITDA break-even in the second half of FY27, alongside the addition of 500 beds across existing facilities requiring minimal capex. Concurrently, management is initiating a 45,000 million INR capex cycle to build 2,700 greenfield beds over 3 to 4 years, funded entirely by internal accruals and project debt. As Noida losses reverse and mature hubs absorb new procedural capacity, operating leverage will drive consolidated margin expansion. The key execution watchpoint is navigating clinical talent attrition risks in Gurgaon while ensuring Noida occupancy scales on schedule.
The economics of this business persist through high barriers to entry, specifically the multi-year qualification cycles required to build clinical trust and secure accreditations like JCI and NABH. Medanta Gurugram has been recognized as the best hospital in India for seven consecutive years, and the Lucknow facility recently became the first in Eastern Uttar Pradesh to receive JCI accreditation in January 2026. These accreditations, combined with a low Average Length of Stay of 3 to 3.06 days and a focus on complex specialties like robotic surgery and transplants, create high switching costs for patients and insurers. The company has not taken a tariff increase in Patna since operations began four years ago, yet continues to see 20 percent plus inpatient volume growth, demonstrating that its growth is volume-driven rather than reliant on pricing power. This niche dominance in underpenetrated regions like Bihar and Eastern Uttar Pradesh protects its margins through cycles.
The inflection point driving the 18 to 24 month picture is the rapid scaling of the Noida facility and the brownfield expansion of existing hospitals. Noida began operations in September 2025 with 226 beds and has already scaled to 382 beds by May 2026, with total income growing from 525 million INR in Q4 FY26 to 855 million INR in Q1 FY27. The Noida EBITDA loss declined sharply from 236 million INR in Q4 FY26 to 49 million INR in Q1 FY27, putting the facility on track for break-even in the second half of FY27. Concurrently, 500 beds will be added across existing hospitals with minimal capex, and 10 operation theaters will be added across Lucknow, Patna, and Gurugram. By FY28, the consolidated margin profile will benefit from the full-year impact of Noida break-even, the maturation of Lucknow into the mature hospital category, and operational efficiencies yielding a couple of hundred basis points of improvement across the system.
Management has demonstrated consistent execution across the last four quarters, upgrading guidance and delivering on promised timelines. In August 2025, they guided that the 550-bed Noida hospital would open in the coming weeks with 300 beds; by February 2026, they confirmed operations began in September 2025 with 328 beds active, exactly matching the promised timeline. FY25 revenue growth guidance of 13 percent was delivered at 13 percent, and EBITDA margin guidance of approximately 25 percent was met at 25.4 percent. They committed to adding 1,000 beds over two years and have already added 537 beds in the first nine months of FY26. The capital allocation stance is conservative, with a net cash position of 5,906 million INR as of FY26 and future growth funded by internal accruals generating 7,144 million INR in operating cash flow. No major guidance misses or downward revisions have been recorded.
Earnings visibility is anchored by the quantified path of Noida break-even and the 45,000 million INR capex pipeline. For the thesis to hold, Noida must achieve EBITDA break-even in the second half of FY27, and mature hospital margins must remain stable in the 24 to 25 percent range despite corporate cost loading onto the Gurugram facility. The single most important watchpoint is the occupancy rate at Noida, currently fluctuating between 30 and 40 percent due to phased bed additions. If occupancy stabilizes above 45 percent by Q3 FY27, the operating leverage will drive consolidated EBITDA margins toward 25 percent. The tension between declining PAT due to Noida depreciation and rising gross margins ex-Noida is purely operational and will resolve as Noida crosses break-even, converting fixed costs into incremental EBITDA.
companyname: Global Health Limited ticker: MEDANTA sector: Healthcare - Multi-specialty Tertiary and Quaternary Care Global Health Limited, operating under the Medanta brand, is one of India's largest private providers of multi-specialty tertiary and quaternary care. The company was founded by Dr. Naresh Trehan, a cardiac surgeon who previously established the Escorts Heart Institute, and commenced operations in 2009 with the flagship Medanta The Medicity in Gurugram. As of FY2025, the company ...
Read the full report →capex, margin expansion, regulatory approval, acquisition inorganic
Medanta will add approximately 2,700 beds through 5 greenfield projects over the next 3 to 4 years driven by expansion projects
Guidance upgradedconsistent
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Global Health Limited and 4,900+ companies.
5-day free pass. No card required.